JN.1-adapted COVID-19 vaccine

The JN.1-adapted COVID-19 vaccines are updated mRNA-based vaccines designed to target the Omicron variant of SARS-CoV-2, specifically the JN.1 lineage and its sublineages such as KP.2 and KP.3[6][2][4]. These vaccines encode a modified spike protein antigen corresponding to the currently circulating variants, aiming to elicit an immune response that provides improved protection against infection and severe disease caused by these strains[6][3]. The adaptation follows recommendations from regulatory agencies including FDA, EMA, and WHO to update vaccine composition in response to viral evolution[6][3]. The primary indication is prevention of COVID-19 in individuals aged six months and older[6][4].

Brand names

Comirnaty JN.1Spikevax JN.1

Other names

Omicron JN.1-adapted monovalent COVID-19 vaccineSARS-CoV-2 mRNA Vaccine (JN.1 lineage)KP.2-adapted COVID-19 vaccine (for the U.S.-market 2024–2025 formula)